Halofenate. Its selection and trial as a primary uricosuric agent

Area of Science:

• Pharmacology
• Biochemistry
• Nephrology

Background:

• Urate homeostasis is crucial for preventing gout and hyperuricemia.
• Acidic anions are known to interact with urate binding proteins.
• Identifying novel uricosuric agents is essential for managing hyperuricemia.

Purpose of the Study:

• To investigate the urate displacement property of anti-inflammatory and uricosuric acidic anions in vitro.
• To establish urate displacement as a marker for predicting in vivo uricosuric activity.
• To evaluate the efficacy and lipid-modulating effects of halofenate in hyperuricemia.

Main Methods:

• In vitro binding studies under physiologic conditions.
• Assessment of urate displacement from protein bonds by acidic anions.
• Long-term clinical evaluation of halofenate for hyperuricemia/gout treatment.
• Analysis of serum lipid concentrations, including triglycerides.

Main Results:

• Acidic anions demonstrated the ability to displace urate from its protein bond in vitro.
• This urate displacement property correlated with potential in vivo uricosuric activity.
• Halofenate proved to be a safe and effective uricosuric agent, comparable to probenecid.
• Halofenate induced a modest, variable reduction in serum lipids but lacked consistent impact on elevated triglycerides in gout patients.

Conclusions:

• Urate displacement is a valuable in vitro marker for identifying potential uricosuric drugs.
• Halofenate is a safe and effective long-term treatment for hyperuricemia/gout.
• While halofenate affects lipid levels, its efficacy in consistently lowering triglycerides in gout patients is limited.